HDAC-7 as novel therapeutic target for human glioblastoma


Glioblastoma is one of the most aggressive and lethal human tumors. We have identified histone deacetylase 7 (HDAC-7) as a potential therapeutic target, a crucial first step toward development of an effective treatment for glioblastoma.

 Market Opportunity

Glioblastoma is the most malignant and aggressive primary brain tumor, with a survival rate of only 14–15 months after diagnosis. The treatment resistance and inevitable tumor recurrence are attributed mainly to the presence of tumor-initiating cells or glioma stem cells, which are characterized by the ability to self-renew, to proliferate indefinitely, and potentially to differentiate into different cell types. Thus, there is a pressing need for innovative therapies for glioblastoma.

 Innovation and Meaningful Advantages

We have identified HDAC-7 as an epigenetic regulator and promising therapeutic target in glioblastoma. We have demonstrated that expression of HDAC-7 is increased in glioblastoma, while its inhibition has a significant effect on tumor growth. Because HDAC-7 is highly expressed in glioblastoma, it represents a good drug target. HDAC-7 knockdown inhibits glioma stem cell properties, transcriptomic expression, and invasion of cancer cells. The identification and chemical synthesis of a specific HDAC-7 inhibitor will enable us to develop a novel RNA therapeutic for HDAC-7.

Collaboration Opportunity

We are interested in exploring 1) startup opportunities with investors; 2) research collaborations with leading pharmaceutical companies; and 3) licensing opportunities with companies.

Principal Investigator

Nikos Tapinos, MD, PhD

Sidney A. Fox and Dorothea Doctors Fox Associate Professor of Ophthalmology, Visual Science, and Neuroscience

Brown University



IP Information

PCT Application Filed, Priority Date: October 12, 2021




Andrew Bond, PhD

Senior Director of Business Development,


Brown Tech ID 3125J

Patent Information:
Therapy Targets
For Information, Contact:
Brown Technology Innovations
350 Eddy Street - Box 1949
Providence, RI 02903
Nikolaos (Nikos) Tapinos
Ola Hassan
David Karambizi
© 2024. All Rights Reserved. Powered by Inteum